Communiqués Boundless Bio, Inc.

Actions

BOLD

US10170A1007

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:32:34 30/09/2026			Varia. 5j.	Varia. 1 janv.
2,510 ^USD	-1,95%		-8,15%	+106,67%

07/08	Boundless Bio, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
23/06	Boundless Bio, Inc. annonce des changements au sein de sa direction, effectifs au 1er juillet 2026	CI

Communiqués

10/09	Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer	AQ
23/06	BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders	BU
23/06	Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement	GL
08/05	Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights	GL
17/04	Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting	GL
17/03	Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026	GL
09/03	Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights	GL
04/03	Boundless Bio to Participate in the Leerink Global Healthcare Conference	GL
05/02	Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026	GL
20/01	Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway	GL
20/01	Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway	AQ
24/11	Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference	GL
24/11	Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference	AQ
05/11	Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights	GL
13/10/25	Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	GL
05/08/25	Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights	GL
05/06/25	Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference	GL
23/05/25	Boundless Bio Announces Portfolio Prioritization and Runway Extension	GL
09/05/25	Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights	GL
03/04/25	Boundless Bio to Participate in the Needham Virtual Healthcare Conference	GL
27/03/25	Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights	AQ
27/03/25	Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights	GL
26/02/25	Boundless Bio to Participate in the Leerink Global Healthcare Conference	GL
03/02/25	Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer	GL
12/12/24	Boundless Bio Announces Pipeline and Leadership Updates	AQ